They Just Don't Get...
Health Care: Drugs
Depomed Inc. (DEPO: NASDAQ)
$5.01 0.01 | 0.20%
06/04/12 - 12:14 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 28.50 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | 189.00 | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | 18.60 | 12.50 |
| Beta | 1.44 | 0.62 | 0.98 |
| Price to Sales (TTM) | 4.18 | 4.29 | 1.42 |
| Price to Book (MRQ) | 2.81 | 4.39 | 2.41 |
| Price to Tangible Book (MRQ) | 2.81 | 14.20 | 5.08 |
| Price to Cash Flow (TTM) | -7.70 | 19.50 | 9.80 |
| Price to Free Cash Flow (TTM) | -8.10 | -327.00 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.90 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.80 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 42.32 | -0.76 |
| Payout Ratio (TTM) | 0.00 | 51.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -79.70 | 15.60 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 64.60 | 9.00 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 36.66 | 6.32 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | -100.00 | -2.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | -100.00 | -2.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | 24.63 | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -36.10 | -6.43 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 2.90 | 1.30 | 1.10 |
| Current Ratio (MRQ) | 3.20 | 1.80 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.29 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.37 | 0.96 |
| Interest Coverage (TTM) | n.a. | 9.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 94.10 | 75.60 | 46.90 |
| Gross Margin - 5 Yr Avg | 93.70 | 75.30 | 47.70 |
| EBITD Margin (TTM) | -54.00 | 29.40 | 18.90 |
| EBITD - 5 Yr Avg | -39.68 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | -54.70 | 18.00 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | 23.50 | 11.80 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -0.55 | 0.14 | 0.09 |
| Net Profit Margin - 5 Yr Avg | 23.30 | 8.60 | 7.00 |
| Return on Assets (TTM) | -24.30 | 7.30 | 3.10 |
| Return on Assets - 5 Yr Avg | 16.70 | 4.60 | 2.50 |
| Return on Investment (TTM) | -37.00 | 10.40 | 7.90 |
| Return on Investment - 5 Yr Avg | 37.40 | 6.50 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 606,427.00 | 404,888.00 | 449,376.00 |
| Net Income/Employee (TTM) | -335,418.00 | 57,122.00 | 39,003.00 |
| Receivable Turnover (TTM) | 4.90 | 4.70 | 7.60 |
| Inventory Turnover (TTM) | 0.80 | 1.70 | 8.30 |
| Asset Turnover (TTM) | 0.40 | 0.60 | 0.40 |
Portfolios with DEPO
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- Usertracking
- UserAccelerant
- UserRASHID 1
- UserPortfolio 02
- UserJan Jan Portfolio 1
- Contributor10 Surging Stocks Most at R...
- Usergbwineman Portfolio 1
- UserLTR7181 Portfolio 1
- Userfrankie'spicks
Latest DEPO Headlines from TheStreet
- Stocks Under $10: Healthcare Name on Sale
05.17.12 | 07:05 am - Depomed: After-Hours Trading 02.03.12 | 05:02 pm
- Depomed Stock Hits New 52-Week Low (DEPO) 10.18.11 | 10:10 am
- Depomed Stock Gaps Down On Today's Open (DEPO) 10.14.11 | 09:10 am
- 7 Stocks to Watch: Google, Apple 10.14.11 | 07:10 am
- Google, Depomed: After-Hours Trading 10.13.11 | 05:10 pm
- Acadia Pharmaceuticals: Investing With No Safety Net 06.24.11 | 10:06 am
- Biotech Stock Mailbag: Star Scientific 03.18.11 | 07:03 am
- 5 Stocks to Watch: Sanmina, UBS 03.17.11 | 07:03 am
- Guess?, DepoMed: After-Hours Trading 03.16.11 | 05:03 pm
Press Releases for DEPO
- Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf - PR Newswire 05.29.12 | 08:05 am
- Depomed To Present At Jefferies 2012 Global Health Care Conference - PR Newswire 05.25.12 | 08:05 am
- Depomed To Present At Bank Of America Merrill Lynch 2012 Health Care Conference - PR Newswire 05.10.12 | 08:05 am
- New 60,000 Square Foot Lease At The Pacific Research Center Signed By Biomed Realty And Depomed - PR Newswire 04.09.12 | 04:04 pm
- Santarus And Depomed Announce Settlement With Lupin Of GLUMETZA Patent Litigation - Business Wire 02.22.12 | 04:02 pm
- Santarus And Depomed Announce New U.S. Commercialization Agreement For GLUMETZA Prescription Products - Business Wire 08.22.11 | 05:08 am
- Ironwood Pharmaceuticals And Depomed Announce Collaboration, Research And License Agreement - Business Wire 07.27.11 | 04:07 pm
- Santarus And Depomed Announce Availability Of GLUMETZA 500 Mg Tablets - Business Wire 01.05.11 | 04:01 am
- New Clinical Study Shows Patients With Type 2 Diabetes May Be Able To Tolerate Higher Doses Of Metformin Using GLUMETZA - PR Newswire 06.28.10 | 08:06 am
- Depomed To Present At The 9th Annual JMP Securities Research Conference - Business Wire 05.04.10 | 08:05 am
Partner Headlines for DEPO
- New Constructs' Most Attractive Stocks for June - Benzinga 06.04.12 | 09:06 am
- The Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Shire, Depomed, Comcast and Microsoft - Press Releases - Zacks 05.18.12 | 09:05 am
- Company News for February 7, 2012 - Corporate Summary - Zacks 02.07.12 | 10:02 am
- 7 Healthcare Stocks Undervalued By Earnings Growth And Cash Flows - Seeking Alpha 02.03.12 | 07:02 pm
- Depomed Announces FDA Approval of Merck's JANUMET XR That Accesses Depomed Patents Licensed to Merck - Benzinga 02.03.12 | 04:02 pm
- Depomed Receives Notice of Paragraph IV Certification Against Patents for Gralise - Benzinga 01.23.12 | 04:01 pm
- BMS Drug Deemed Too Costly: Weekly Round-Up Of Biotech Failures And Mishaps - Seeking Alpha 10.16.11 | 08:10 am
- UPDATE: Zacks Upgrades DepoMed from Neutral to Outperform - Benzinga 08.10.11 | 09:08 am
- 5 Highly Profitable Stocks Undervalued by EPS Trends - Seeking Alpha 07.11.11 | 06:07 am
- Contrarian Ideas: 25 High Growth Stocks With Significant Short Selling - Seeking Alpha 06.06.11 | 08:06 am
